Toolkits07 · In-licensing and BD evaluation
Item 07 · in-licensing and bd evaluation · KSA and GCC consumer healthcare

In-licensing and BD evaluation: one offer, one decision meeting

A 27-slide evaluation of a licensing offer or a range for sale — fit, market, price chain per SKU, forecast, returns, due-diligence list, contract points, tracker, screen and verdict — with the workbook that scores it.

Slide 3 from the In-licensing and BD evaluation example (watermarked preview)
From the worked example: slide 3 of 27. Every preview carries a watermark; the files do not.

8 slides from the example

Slides 1 · 3 · 7 · 10 · 15 · 18 · 25 · 26 of 27 · click to enlarge
Slide 1
Slide 3
Slide 7
Slide 10
Slide 15
Slide 18
Slide 25
Slide 26

2 sheets from the workbook

Returns · Screen · click to enlarge
Sheet: Returns
Sheet: Screen
The problem it solves

Offers are accepted on the licensor's forecast and regretted on the shortfall clause. This evaluation builds our own number per SKU, screens it against hard gates, lists the diligence questions with owners and turns the open ones into conditions to sign.

What is inside
  • BD Evaluation Template (27 slides)
  • BD Evaluation Example — Halvena baby range, KSA (27 slides, fictional)
  • BD Evaluation Workbook (Inputs → SKU shortlist → Forecast → Returns → Screen → DD list → Contract → Tracker → Checks; 451 formulas) + example
  • Two-page how-to
Template: 27 slides. Example: 27 slides. How-to.pdf (2 pages).
Who it is for

Business-development lead, portfolio lead, country manager in consumer healthcare, writing for a Gulf market and presenting to a regional or global team. Also the distributor marketer who co-writes it.

How the example helps

Every example is set in one fictional world: Meridian Consumer Health, its distributor Northern Gulf Distribution Co., the scalp-care brand Clarisel and its competitors Scalvia, Sebravel, Scalpex and Trichoderm. Nahdi, Al-Dawaa and United are real Saudi pharmacy chains used as market fixtures with invented figures. You see every box filled, every chart populated and every number reconciled, without a real company's data.

Not for

Prescription brands with a medical-affairs plan, agencies pitching creative work, or anyone who needs a company's proprietary template. The structure is the practice of the industry; the words, charts and numbers are original.

Writing this in the next eight weeks?

The done-with-you option adds three working sessions on your own document: inputs and numbers, the draft, and a review against the questions head office will ask.

Ask about a session